BeiGene, Ltd. (BGNE)
| Previous Close | 144.94 |
| Open | 144.69 |
| Bid | 142.52 x 1100 |
| Ask | 143.09 x 800 |
| Day's Range | 138.01 - 144.69 |
| 52 Week Range | 118.18 - 392.30 |
| Volume | |
| Avg. Volume | 223,348 |
| Market Cap | 14.725B |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.05 |
| Earnings Date | Aug 08, 2018 - Aug 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 271.64 |
- Bloomberg
Latest Push by Chinese Firms to Avoid Delistings Falls Short
(Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark
- Business Wire
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have
- Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of BRUKINSA ® (zanubrutinib) for the treatment o
